Open-label Extension Study of Brazikumab in Crohn’s Disease

Trial Identifier: D5271C00002
Sponsor: AstraZeneca
NCTID:: NCT03961815
Start Date: January 2020
Primary Completion Date: September 2023
Study Completion Date: September 2023
Condition: IBD

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Afrikaans Translation
Arabic Translation
Czech Translation
German Translation
German Translation
English Translation
English Translation
Spanish Translation
Spanish Translation
French Translation
French Translation
Gujarati Translation
Hebrew Translation
Hindi Translation
Hungarian Translation
Italian Translation
Kannada Translation
Korean Translation
Marathi Translation
Polish Translation
Russian Translation
Russian Translation
Slovak Translation
Tamil Translation
Telugu Translation
Ukrainian Translation
Chinese Translation

Trial Locations

Country Location
DE Hamburg, DE, 20251
IT BOLOGNA, IT, 40138
PL Rzeszow, PL, 35-302
TW Taichung, TW, 40443
US, CA Lincoln, CA, US, 95648
US, FL Clearwater, FL, US, 33756
US, FL Kissimmee, FL, US, 34741
US, FL Lakeland, FL, US, 33813
US, FL Miami, FL, US, 33165
US, FL Miami, FL, US, 33157
US, FL Miami Lakes, FL, US, 33016
US, FL Tampa, FL, US, 33626
US, OH Beachwood, OH, US, 44122
US, TX Houston, TX, US, 77058
ZA Cape Town, ZA, 7500
ZA Plumstead, ZA, 7800